SOPH (Sophia Genetics) Moat Score: 5/10 (As of Jul. 02, 2026)


SOPH Sophia Genetics SA SOPH
73 GF Score
Price $5.54
GF Value $5.04
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sophia Genetics Moat Score?

Sophia Genetics SOPH -0.72% 73 Moat Score is 5 as of Jul. 02, 2026. GuruFocus rates SOPH with a GF Score™ of 73/100 and a GF Value™ of $5.04 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 679 Healthcare Providers & Services companies, Sophia Genetics ranks better than 96.02% on this metric.

Sophia Genetics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Sophia Genetics has Narrow Moat: Sophia Genetics SA has a solid position in the genomics data analysis market, with some proprietary technology and customer switching costs. However, it faces competition from larger players, limiting its ability to expand its moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sophia Genetics might have Narrow Moat - Solid narrow moat.

Sophia Genetics  (NAS:SOPH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sophia Genetics Moat Score Related Terms

SOPH vs WEAV, NRC, MDRX: Moat Score Comparison

For the Health Information Services subindustry, Sophia Genetics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sophia Genetics Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Moat Score distribution charts can be found below:

* The bar in red indicates where Sophia Genetics's Moat Score falls into.


SOPH
73GF Score
Sophia Genetics SA SOPH
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Sophia Genetics (SOPH) has a Moat Score of 5 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sophia Genetics ranks #27 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 4%.
Is Sophia Genetics' Moat Score too high?
Sophia Genetics' current Moat Score is 5. Based on the distribution chart, Sophia Genetics ranks #27 out of 679 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Sophia Genetics has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Moat Score compare to WEAV and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #27 out of 679 companies for Moat Score. This places Sophia Genetics in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Sophia Genetics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.04, compared to a current price of $5.54 — trading 9.9% above its estimated fair value. The current Moat Score is 5. Sophia Genetics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current Moat Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sophia Genetics (SOPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued. The current stock price of $5.54 is trading 9.9% above its estimated GF Value™ of $5.04. GuruFocus considers Sophia Genetics to be Modestly Overvalued.

Key valuation signals for SOPH:

  • Moat Score: 5
  • GF Value™: $5.04 vs. price of $5.54 (9.9% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sophia Genetics Business Description

Other Exchanges 90B:Germany
Address La Piece 12, Rolle, CHE, CH-1180
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
73GF Score

Get the complete analysis for SOPH

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.54
Price
$5.04
GF Value